Germany Allergy Therapeutics Market Analysis

Germany Allergy Therapeutics Market Executive Summary

Germany Allergy Therapeutics Market was valued at $849 Mn in 2022 and is estimated to reach $1217 Mn in 2030, exhibiting a CAGR of 4.6% during the forecast period.

Allergens are substances from the environment that, in certain cases, trigger an immunological reaction. Dust mites, pollen, mold, and specific foods like milk, eggs, soy, and almonds are examples of common allergies. From minor symptoms like a runny nose and itchy eyes to severe ones like anaphylaxis, which can result in breathing problems and unconsciousness, allergic responses can take many different forms. Immunotherapy, avoiding allergens, and using prescription drugs, including antihistamines and nasal corticosteroids, are some of the available treatment options.

About 8% of adult Germans today have bronchial asthma, which includes allergic asthma. Furthermore, allergies account for roughly one-third of adult cases (31%), encompassing hay fever, skin or eye allergies, food allergies, and other allergens (apart from allergic asthma). Compared to men, women reported a higher frequency of allergy disorders.Allergy to hay fever was diagnosed in about 16% of individuals, making allergic rhinitis the most common allergy condition. The lifetime incidence of bronchial asthma is roughly 9%, and the prevalence of allergic contact dermatitis in adults is also approximately 9%. Food allergies (5%), atopic dermatitis (4%), and insect venom allergy (3%), on the other hand, are less common and more commonly affect women than males.

IgE antibodies specific to environmental allergens were identified in 50% of Germany's adult population. There was variation in the rates of sensitization: 34% were sensitized to a combination of inhaled allergens, 26% to food allergens, 19% to pollen from grass and trees, and 11% to pollen from herbs. The prevalence of hay fever in children and adolescents is 11%, while bronchial asthma affects 6% of the population. Females had a greater lifetime prevalence of atopic dermatitis (13%), but boys received bronchial asthma diagnoses more often. Between 14% and 37% of children and adolescents reported being sensitized, with boys typically exhibiting higher rates than girls.The German population has a high prevalence of allergy disorders and sensitization, which highlights the necessity for ongoing research and practical treatment techniques to address these health concerns.

The development of sublingual immunotherapy (SLIT), an oral form of allergy immunotherapy (AIT), is being driven by German research institutes and pharmaceutical companies. Comparing SLIT to subcutaneous immunotherapy, recent research shows encouraging results in the treatment of pollen allergies, with possible benefits including reduced side effects and improved patient compliance.

Market Dynamics

Market Growth Drivers

Prevalence of Allergies: The rising incidence of allergies, particularly environmental allergies and respiratory allergies like hay fever, is driving the need for efficient allergy treatment medications. Urbanization and environmental changes are two factors that may be contributing to an increase in the prevalence of allergies.

Rising Awareness and Diagnosis: An increasing number of cases are being diagnosed as a result of growing awareness of allergies and improvements in diagnostic tools. People are more inclined to seek out pharmacological and medical interventions for their allergy problems as awareness increases.

Aging Population: There is a growing probability that people may experience allergies or acquire new allergies as they become older, which fuels the ongoing need for allergy medications. The range of allergic disorders is wide, and the prevalence of allergic diseases in the elderly population is high and growing. Due to their aging immune systems, which may find it more difficult to fend off minor allergic reactions to triggers like pollen, the elderly are more vulnerable to the symptoms of allergies.

Market Restraints

High Cost of Treatment: Due to their exorbitant cost, many of the most successful current allergy therapies, such as biologics and sublingual immunotherapy, are out of reach for a significant portion of the population. This financial barrier can restrict the market's adoption of these medications and keep patients from getting the best care available.

Treatment Compliance and Adherence: The efficacy of allergy medications, particularly immunotherapy therapies, depends on patients' continuous adherence to extended treatment plans. Obstacles like exorbitant expenses, complexity, or unsatisfactory outcomes resulting in insufficient patient compliance may reduce the effectiveness of treatment and hinder market growth.

Cultural and Behavioural Factors: Market penetration may be hampered by certain groups preference for traditional medications or home cures over contemporary treatments. Decreased awareness within a community could make it harder to identify and comprehend allergy symptoms, which would postpone diagnosis and treatment. Notwithstanding these difficulties, there is rising interest in the use of non-pharmaceutical strategies, such as air filters, to reduce allergens and/or avoid allergy symptoms.

Notable Recent Updates

• October 2023, German generic drug specialist Dermapharm purchased Merck KGaA's Allergopharma division, which included a production facility and a range of therapeutic and diagnostic treatments for treating type 1 allergies, such as hay fever.

Healthcare Policies and Regulatory Landscape

The Federal Ministry of Health (BMG), which is in charge of creating national healthcare policies, and the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM), which is in charge of primary regulatory oversight for drug approvals and guarantees safety, efficacy, and quality, are the key organizations in Germany that coordinate healthcare policies and regulatory oversight pertaining to allergy treatment drugs. In particular, the regulatory environment pertaining to biomedicines is influenced by the Paul-Ehrlich-Institute (PEI). The German Medicines Agency (AMB) works with partners to conduct drug surveillance, and the Institute for Quality and Efficiency in Health Care (IQWiG) evaluates the risks and benefits of medical therapies. Different Health Technology Assessment (HTA) committees assess the value and cost-effectiveness of healthcare interventions, and the Federal Joint Committee (G-BA) has an impact on reimbursement choices. Drug pricing talks involve the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband). According to European Medicines Agency rules, this regulatory system requires enterprises to go through rigorous processes for clearance and compliance before market authorization and reimbursement considerations are handled

Competitive Landscape

Key Players

• Novartis
• GlaxoSmithKline (GSK)
• Sanofi
• Roche
• Merck & Co.
• Johnson & Johnson
• AstraZeneca
• Bayer
• Boehringer Ingelheim
• Allergan